CTDSPL

Across TCGA pan-cancer cohorts, CTDSPL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CTDSPL data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CTDSPL mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CTDSPL expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where CTDSPL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	III,IV	0.083	0.721	.038	6	view →
HNSC	DFS	Tertile	II,III,IV	0.701	1.000	.036	6	view →
LUAD	OS	Median	II,III,IV	0.806	0.482	.010	3	view →
CCRCC	OS	Median	All	0.941	0.748	.017	3	view →
UCEC	DFS	Quartile	All	0.763	1.000	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CTDSPL–PDAC (DFS)

Open the PDAC breakdown →